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Under physiological conditions, in vitro interaction between favipiravir (FAV) and serum albumins 
(BSA/HSA) was investigated at excitation wavelength 280 nm and at different temperatures (298 K, 
313 K) by fluorescence emission spectroscopy. The hydrogen bond, van der Waals forces and 
electrostatic interaction plays a major role in stabilizing the complex; the binding constants KA at 
different temperatures were calculated. The distance r between donor (BSA/HSA) and acceptor 
(FAV) was obtained according to fluorescence resonance energy transfer (1.55/1.90 nm for 
BSA/HSA-FAV systems). The effect of FAV on the conformation of BSA/HSA was analyzed using 
synchronous fluorescence spectroscopy and UV/vis absorption spectroscopy. 
________________________________________________________________________________ 
Introduction 
A novel coronavirus, SARS-CoV-2, 
emerged in December 2019 in Wuhan, China. As 
the scale of the ongoing COVID-19 outbreak has 
reached pandemic proportions, significant 
interest exists in repurposing existing antiviral 
agents for use against COVID-19 [1]. Favipiravir 
(FAV) is an oral antiviral approved for the 
treatment of influenza in Japan. This drug is a 
purine nucleoside analogue, which acts as a 
competitive inhibitor of RNA polymerase, which 
is necessary for viral replication [2]. It has 
activity against influenza A and B, Ebola virus 
and SARS-CoV-2 in vitro [3]. 
Serum albumins are the most abundant 
protein in plasma, and participate in the binding 
and transportation of various drugs. Among 
albumins, bovine serum albumin (BSA) and 
human serum albumin (HSA) have been widely 
used as models for studying the interaction of 
drug with protein in vitro [4, 5]. It is a convenient 
protein for intrinsic fluorescence measurement 
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due to the presence of tryptophan (Trp) residues 
which is highly sensitive to its local environment, 
and can be used to observe changes in the 
fluorescence emission spectra due to protein 
conformational changes and binding to 
substrates [6]. Therefore, study of the interaction 
between protein and drug molecules will help 
provide basic information on the 
pharmacological actions, bio-transformation, 
bio-distribution of drugs. 
There are a number of reports in the 
literature, where binding of metabolites, drugs, 
dyes, fatty acids, bio-active-substances have 
been studied in detail. So the nature of binding of 
a ligand with HSA (BSA) is different for 
different ligands [7]. 
In recent years, a few research groups [8 
- 22] reported the interactions between various 
antiviral drugs and serum albumins by 
fluorescence, UV–vis spectra, synchronous 
fluorescence, circular dichroism, and 3D 
fluorescence spectra.  
In the present work, the interaction between FAV 
and BSA/HAS has been investigated in vitro 
using fluorescence, UV–vis and synchronous 
fluorescence spectra techniques under 
physiological conditions. The association 
constants, the thermodynamic parameters, the 
number of binding sites, and the energy transfer 
distance of FAV-BSA/HSA complexes were 
estimated. At the same time, the effect of FAV 
on the microenvironment and conformation of 
proteins was discussed. In addition, the binding 
mechanism of FAV with BSA/HSA was 
explored. These studies will be useful to design 




Bovine serum albumin (BSA, 98% purity, 
Mr = 68000), and human serum albumin (HSA, 
98% purity, Mr = 66000) purchased from Sigma–
Aldrich, were used without further purification. 
They were both dissolved in the Tris–HCl buffer 
solution (pH 7.4) to form a solution of 1 × 10-4 
mol L-1and then stored in the dark at 4 ºC.  
Favipiravir (FAV, 99% purity) was 
obtained from Cangzhou Wisdom Pharma Co., 
Ltd (China). FAV stock solution (1 × 10–2 mol 
L−1) was prepared by dissolving 0.157 g of 
substance in 100.0 mL of water. The working 
solution (1 × 10–4 mol L−1) was prepared daily by 
diluting the stock solution with water.  
 
Scheme 1. The structure of FAV 
Tris (hydroxymethyl) aminomethane 
(purity ≥99%) and sodium chloride (purity 
≥99.5%) were purchased from Sigma-Aldrich. 
Tris–HCl buffer solution (0.05 mol L−1, 
containing 0.15 mol L−1 NaCl) was used to 
maintain the pH of the solutions at 7.40. 
All of the used chemicals were of 
analytical reagent grade and also used without 
further purification. Doubly distilled water was 
used throughout the experiment. 




Absorption spectra were recorded at room 
temperature on a UV-2401 PC 
spectrophotometer (Shimadzu) equipped with 
1.0 cm quartz cells.  
A Cary Eclipse spectrofluorimeter 
(Varian) equipped with a 1.0 cm quartz cell was 
applied to monitor all fluorescence spectra. The 
excitation wavelength was 280 nm, and the 
fluorescence emission spectra were recorded in 
the wavelength range of 285–550 nm. The slit 
width of λex/λem was set at 5/5 nm for steady-state 
fluorescence spectroscopy, and synchronous 
fluorescence spectroscopy. Fluorescence 
emission spectra were measured at 298 and 313 
K. 
To obtain different temperatures a 
waterbath (WNB 14 Memmert GmbH, 
Germany) was used. The pH values of solutions 
were measured on Seven Easy pH meter (Mettler 
Toledo) with a glass electrode. 
Procedures 
For steady-state quenching studies, the 
BSA/HSA solution with the fixed concentration 
of 1 × 10–5 mol L–1 was titrated by successive 
additions of FAV (1 × 10–6 mol L–1 –  
5 × 10–4 mol L–1) under physiological conditions 
(pH 7.4) at two different temperature (298, and 
313 K). All solutions were mixed thoroughly and 
kept 5 min before measurements.  
FAV has intrinsic fluorescence with a 
maximum at 430 nm which does not interfere 
with protein quenching.  
The UV-vis absorbance spectra were recorded 
at room temperature. A fixed concentration of 
BSA/HSA (5 × 10–6 mol L–1) with various 
concentration of the FAV solution (5 × 10–5; 1 × 
10–4; 2 × 10–4 mol L−1), 1 mL Tris-HCl buffer 
were added and the solutions were diluted to 10 
mL with water. The corresponding solution of 
the FAV was used as the reference solution.  
In the present work, the inner-filter effect can 
be considered negligible due to the very low 
absorbance value of FAV at the excitation 
wavelength of BSA/HSA. For example, all 
figures are for BSA. 
Results and discussion 
UV–vis absorption spectra experiments 
UV–vis absorption measurement is a simple 
method that is used to investigate structural 
changes and to explore complex formation [23]. 
FAV exhibited three peaks at 228 nm, 323 nm, 
and 363 nm (Figure 1, а).  
To initially verify the quenching mechanism, 
the UV absorption spectra of (BSA/HSA) and 
((BSA/HSA + FAV)- FAV) were recorded. As 
shown in Figure 1, b, BSA possessed two 
absorption peaks at 220 nm and 280 nm. The 
strong absorption peak at around 220 nm 
reflected the absorption of the backbone of BSA, 
while the weak absorption peak at around 280 nm 
resulted from the aromatic amino acids (Trp, Tyr, 
and Phe). With varying concentration of FAV, a 
noticeable decrease in the absorbance intensity of 
the peak at 220 nm coupled with a red shift of the 
maximum wavelength (about 2 nm) was 
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observed, which indicated that there was a 
variation in the framework conformation of BSA 
due to the formation of FAV-BSA complex. 
These changes further reconfirmed that static 
quenching was dominant in the interaction 
process. 
Fluorescence quenching spectra  
Any process, which decreases the 
fluorescence intensity of a sample, is called 
fluorescence quenching. Fluorescence detection 
is a highly sensitive method for exploring the 
change in the fluorophore environment upon 
quencher interaction, hence resulting of 
considerable information regarding the binding 
mechanism. 
The interaction of FAV with BSA was 
evaluated by monitoring the intrinsic 
fluorescence intensity changes of proteins upon 
addition of FAV (Figure 2). The emission of 
BSA/HSA was characterized by a broad 
emission band at 348 nm (BSA) and 330 nm 
(HSA). BSA/HSA fluorescence intensity 
decreased remarkably as FAV concentrations 
increased. FAV produced ~10% quenching in 
BSA/HSA fluorescence intensity, which was 
accompanied by a 28 nm blue shift in the 
emission maximum at the same ligand 
concentration. The shift in the emission 
maximum of BSA/HSA towards shorter 
wavelength suggested increased hydrophobicity 
in the microenvironment of the protein 
fluorophores upon interaction with this 
compound [24]. This indicated that FAV could 
interact with BSA/HSA. 
Analysis of the emission change of 
BSA/HSA with various amounts of FAV was 





qSV                     (1) 
where F0 and F are the fluorescence 
intensity in the absence and presence of the 
quencher, respectively, Q the quencher 
concentration, and kq the quenching rate constant 
for a biomolecular reaction, KSV the Stern–
Volmer quenching constant and τ0 is the average 
lifetime for fluorophore in the absence of 
quencher evaluated at 10-8 s [25]. 
Figure 3 shows plots of F0/F versus FAV 
concentrations at different temperatures. They 
exhibit good linear correlations. It is clear that 
plots in Fig. 3 are approximately consistent with 
the Stern–Volmer equation, from which the 
Stern–Volmer quenching constant KSV are 
derived and are listed in Table 1. A quenching 
process can be usually induced by a collisional 
process and/or a formation of a complex between 
quencher and fluorophore. The values for 
quenching rate constants in Table 1 are of the 
magnitude of 1012 L mol-1 s-1. Obviously, the 
quenching rate constant kq for FAV– BSA/HSA 
is greater than that of a scatter process. 




Figure 1. Absorption spectrum of FAV (cFAV = 1 × 10−4 mol L−1) (a); effect of FAV on UV absorption spectra of BSA 
(b) (T= 298 K, pH 7.4, cBSA = 5 × 10-6 mol L−1, cFAV × 10-4 mol L−1, 1-4: 0, 0.5, 1.0, 2.0 (2-4 - difference absorption 
spectrum between FAV - BSA and FAV). 
It may be attributed a quenching process 
initiated by bioactive substances. So it shows that 
the above quenching was not initiated by 
dynamic collision but forms compound, it was 
static quenching. Furthermore, linear Stern–
Volmer plots may either reveal the occurrence of 
just a binding site for quencher in the proximity 
of the fluorophore or indicate the existence of a 
single type of quenching [26]. 
When small molecules are bound 
independently to a set of equivalent sites on a 
macromolecule, the binding constant (KA) and 





                          (2) 
where F0 and F are the fluorescence intensity in 
the absence and presence of bioactive substance, 
respectively. There is a good linear correlations 
for the plots obtained by Eq. (2). 
 
Figure 2. Fluorescence emission spectra of BSA in the 
presence of FAV various amounts (cFAV × 10−4 mol L−1, 
curves (1-13): 0, 0.01, 0.03, 0.05, 0.07, 0.1, 0.2, 0.5, 0.7, 
1.0, 2.0, 3.0, 5.0; pH 7.4, λex = 280 nm,  
cBSA = 1 × 10-5 mol L−1, T= 298 K). 
 
The values for KA and n derived from 
according Eq. (2) and listed in Table 2. 
They indicate that the amount of FAV will 
affect the pattern of FAV binding to BSA/HSA. 
The influence of temperatures on the FAV 
binding to BSA/HSA is significant. It is obvious 
that higher temperature will lead to a rapid 
collision, whereas results in a decrease in the 
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binding strength. As a result, KA and n will 
decrease with raising temperature. 
Furthermore, the value for n close to one, we 
may infer that there exists only one kind of 
binding site on BSA/HSA for FAV binding. 
Binding mode 
There are several intermolecular forces 
causing small drug molecules binding to 
proteins, such as hydrogen bonding, van der 
Waals, ionic, electrostatic and hydrophobic 
interactions, etc. 
 
Figure 3. Stern-Volmer plots for quenching of BSA 
fluorescence by FAV at different temperatures (pH 7.4, λex 
= 280 nm, cBSA = 1 × 10-5 mol L−1; ♦ - 298 K; ■ – 313 K). 
 
Table 1. Stern-Volmer quenching constant Ksv, bimolecular quenching rate constant kq of the BSA/HSA-FAV system at 
different temperatures, R represents the correlation coefficients of the plots 
T(K) Albumin KSV·× 10-4(L mol-1) R SD kq × 10-12 (L mol-1 s-1) 
298 
BSA 
2.73 0.9821 0.85 2.728 
313 1.76 0.9981 0.18 1.760 
298 
HSA 
5.38 0.9976 0.06 5.384 
313 4.94 0.9974 0.06 4.944 
Table 2. Binding constant KA, the number of binding sites n and distance between acceptor and donor r at different 
temperatures and thermodynamic parameters of FAV-BSA/HSA interaction,  
R represents the correlation coefficients of the plots 
T(K) Albumin 
KA × 10-3  
(L mol-1) 













313 46.33 1.100 0.9809 1.62 -27.96 
298 
HSA 




313 0.48 0.727 0.9914 1.92 -16.05 
 
The signs and magnitudes of thermodynamic 
parameters for protein reactions can be 
accounted for the main forces contributing to 
protein stability. The values for the enthalpy 
change (ΔHº) and entropy change (ΔSº) will be 
derived from the van’t Hoff equation by 
y = 0,0273x + 0,6452
R² = 0,9646
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considering ΔHº not varying significantly over 









ln                                    (3)  
where KA is the binding constant at a definite 
temperature T and R is the gas constant. 
Consequently, the amount of free energy change 
ΔGº required for the binding is estimated from 
the following equation: 
 STHG                                    (4) 
The data for ΔHº and ΔSº of FAV binding to 
BSA/HSA are summarized in Table 2. With 
respect to recognized literature data on analogous 
systems [27], the positive ΔSº and negative ΔHº 
values suggested that there was specific 
electrostatic interactions between FAV and BSA, 
the negative values of  ΔHº and ΔSº can be 
attributed in part to van der Waals forces and in 
part to the formation of hydrogen bonds for 
HSA-FAV. 
Energy transfer from BSA/HSA to FAV 
Energy transfer between drugs and proteins 
usually can be divided into two kinds: radiative 
energy transfer and non-radiative energy 
transfer. The latter can be explained and 
determined by Foster’s energy transfer theory - 
fluorescence resonance energy transfer (FRET). 
In this interaction, excitation energy is 
transferred from one molecule (donor) to another 
(acceptor) through direct electrodynamic 
interaction, without emission of a photon from 
the former molecular system [28]. Energy 
transfer may occur under the following 
conditions: when the donor can produce 
fluorescent light; when there is an overlap 
between the fluorescence emission spectrum of 
the donor and the absorbance spectrum of the 
acceptor; and when the distance between the 
donor and the acceptor is less than 8 nm. The 
efficiency of energy transfer between FAV and 
the BSA/HSA Trp-residue could be used to 
evaluate the distance between the two using 
FRET. The overlap of the absorbance spectrum 
of FAV with the fluorescence emission spectrum 
of BSA has been shown in Figure 4. 
 
Figure 4. Overlap of the absorption spectrum of FAV (1) 
with the fluorescence emission spectrum of BSA (2) 
(cBSA/cFAV = 1:1, 1 × 10-4 mol L−1; T = 298 K; pH 7.4; 
λex = 280 nm). 
 
According to Forster’s non-radiative 
resonance energy transfer theory [29], energy 
transfer efficiency E is related not only to the 
distance (r) between the bound bio-active 
molecule (acceptor) and the protein residue 
(donor), but also to the critical energy transfer 
distance (R0). By Forster’s theory, the efficiency 
of energy transfer (E) can be calculated 
according to the following equation: 
)/(/1 660
6
00 rRRFFE                       (5) 
where r is the distance between acceptor (FAV) 
and donor (BSA/HSA), and R0 is the critical 
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distance when the transfer efficiency is 50%. The 
value of R0 is calculated using the following 
equation:  
JnKR 422560 1079.8
                             (6) 
where K2 is the spatial orientation factor of the 
dipole; n is the refractive index of the medium; φ 
is the fluorescence quantum yield of donor; and 
J is the spectral overlap between the emission 
spectrum of donor and the absorption spectrum 















J                                    (7) 
where F(λ) is the normalized fluorescence 
intensity of the donor at wavelength λ, and ε(λ) 
is the molar absorption coefficient of the acceptor 
at wavelength λ. In the present case, K2 = 2/3, n 
= 1.336, and φ = 0.15 (BSA), φ = 0.118 (HSA) 
[30]. Hence, from equations (5)–(7), we could 
calculate the following parameters are listed in 
Table 3. In conclusion, the distance (r) between 
BSA/HSA Trp residues and bound FAV was 
much less than 8 nm, and accorded with the 
relationship 0.5R0 < r <1.5R0. This implied that 
the non-radiative energy transfer from BSA/HSA 
to FAV occurred with high possibility, which 
was in accordance with the occurrence of a static 
quenching mechanism. This result indicated that 
the binding obeyed the conditions of Forster’s 
energy transfer. A comparison of the J, R0 and r 
values of different ligands bound to proteins is 
given in Table 3. As can be seen from this table, 
the values of these parameters are comparable.  
Synchronous Fluorescence Spectroscopy 
The possible shift of the maximum emission 
wavelength is related to the change in polarity 
around the fluorophore molecule. When the 
scanning interval (Δλ) between the excitation and 
the emission wavelength is fixed at 15 and 60 
nm, this provides the characteristic information 
on the Tyr and Trp residues of the protein, 
respectively [31]. The results of the synchronous 
fluorescence spectra of BSA with increasing 
concentration of FAV were represented in Fig. 5 
(a) and (b). Synchronous fluorescence spectra at 
Δλ = 60 nm and Δλ =  
15 nm show a hypsochromic shift (from 282 nm 
to 269 nm and from 286 nm to 282 nm, 
respectively), which indicates the presence of 
changes in protein conformation near tryptophan 
and tyrosine residues. However, the pitch of 
quenching of Trp residues was more obvious 
than that of Tyr residues, which revealed that 
FAV was closer to Trp residues compared to Tyr 
residues. 
Conclusions 
In this work, the interaction between FAV and 
serum albumins (BSA/HSA) have been 
investigated by fluorescence method combined 
with UV–vis spectroscopy techniques under 
simulative physiological condition. 
The experiment results indicate that FAV 
quenches the intrinsic fluorescence of proteins 
through static quenching mode of  
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Table 3. Comparative assessment of the FAV (ligand) distance to proteins (BSA/HSA) measured by Forster’s 
nonradiative energy transfer with other ligands bound to proteins 
Ligand Protein J (cm3 L mol−1) R0 (nm) r (nm) KA (L·mol-1) Ref 
amodiaquine HSA 2.09 × 10−14 2.68 4.59 1.38 × 103 [8] 
darunavir BSA 4.25 × 10–15 2.13 3.13 1.26 × 104 [9] 
ribavirin BSA 1.65 × 10–13 4.26 5.43 1.58 × 104 [10] 









5.43 × 103 





HSA - - - 
3.86 × 103 [14] 
telaprevir HSA - - - 2.56 × 104 [15] 
tenofovir HSA - - - 1.03 × 104 [16] 
MIQ HSA 7.35 × 10–14 2.83 2.37 2.55 × 104 [17] 
zidovudine HSA - - - 2.74 × 102 [18] 
atazanvir BSA - - - 1.48 × 103 [19] 
tilorone HSA 7.88 × 10–16 1.67 1.63 7.19 × 104 [20] 
dolutegravir sodium HSA 3.16 × 10–15 2.03 2.14 9.82 × 103 [21] 
daclatasvіr 
dihydrochloride 
HSA 1.04 × 10–15 1.69 1.42 
8.13 × 104 [22] 
favipiravir BSA, 
HSA 
7.33 × 10–15 





5.62 × 104 






Figure 5. Synchronous fluorescence spectra of BSA with increasing concentration of FAV (Δλ = 60 nm (а) and Δλ =  
15 nm (b); cBSA = 1 × 10-5 mol L−1; (cFAV × 10−4 mol L−1, curves (1-13): 0, 0.01, 0.03, 0.05, 0.07, 0.1, 0.2, 0.5, 0.7, 1.0, 
2.0, 3.0, 5.0). 
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FAV-BSA/HSA system, which supported the 
BSA/HSA UV spectral shifts and the decreasing 
binding constant for FAV and BSA/HSA 
complex with increasing temperature indicates 
the decomposition of the system. 
The values of binding constant and the 
number of binding sites of the FAV-BSA/HSA 
system are determined using the Stern-Volmer 
equation. The average binding distance between 
donor and acceptor molecules was found from 
the Forster non-radioactive resonance energy 
transfer theory 1.55/1.90 nm for BSA/HSA-FAV 
systems. 
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